MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes

MHRA authorised Onswik (insulin efsitora alfa), a once-weekly basal insulin injection, for adults with type 2 diabetes. The agency reports that clinical trial data showed blood glucose control comparable to once-daily basal insulin treatments.

Why it matters: MHRA identifies hypoglycaemia as the most common reported adverse reaction and says safety monitoring will continue after authorisation.